Comment on Biogen profit smashes estimates on Spinraza demand

Biogen profit smashes estimates on Spinraza demand

(Reuters) - Biogen Inc's second-quarter profit blew past estimates, driven by higher-than-expected demand for its recently approved spinal muscular atrophy (SMA) drug, Spinraza.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News